Receptor News and Research

RSS

UCSD scientists discover steroid hormone that inhibits brain inflammation

Researchers at the University of California, San Diego School of Medicine have discovered a steroid hormone that inhibits inflammation in the brain. The findings, to be published in the May 13 issue of the journal Cell, have implications for understanding the exaggerated inflammatory responses that are characteristic features of numerous neurodegenerative diseases.

13 May 2011

Coffee provides protections from a type of breast cancer: Study

For the study they compared coffee consumption in postmenopausal women with breast cancer and women of the same age without cancer, they found those who drank five or more cups of java a day showed a 0.43 times lower risk of estrogen-receptor negative cancers. Around one in four women diagnosed with breast cancer will have estrogen-receptor negative breast cancer, which is often resilient to drug treatment and requires intensive chemotherapy.

12 May 2011

Researchers help explain why smart drugs are not effective in some cancer patients

Some of the most effective and expensive cancer drugs, dubbed "smart drugs" for their ability to stop tumors by targeting key drivers of cancer cell growth, are not effective in some patients. In two related studies, Yale School of Medicine researchers examined one such driver, the EGF receptor, and found that a decoy receptor might be limiting the amount of drug that gets to the intended target.

12 May 2011

Losartan therapy improves muscle injury regeneration and prevents disuse atrophy

Using geriatric mice, a Johns Hopkins research team has shown that losartan, a commonly used blood pressure drug, not only improves regeneration of injured muscle but also protects against its wasting away from inactivity.

12 May 2011

Amira to present AM152 preclinical data in fibrotic disease at ATS Annual Meeting

Amira Pharmaceuticals, Inc. announced today that it will present preclinical data on AM152, an LPA1 receptor antagonist, during the Annual Meeting of the American Thoracic Society in Denver, Colorado.

12 May 2011

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard, the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies SAS, a diagnostic company specialized in innovative immunomonitoring tests and services, today announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, and a chemotherapeutic agent, XELODA, in the treatment of metastatic breast cancer.

11 May 2011

Naurex announces completion of $18 million Series A financing

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the completion of an $18 million Series A financing led by Adams Street Partners and Latterell Venture Partners.

11 May 2011

Women with invasive breast cancer can benefit from new genomic test

A new genomic test combining multiple signatures - a patient's estrogen receptor status, endocrine therapy response, chemotherapy resistance and sensitivity - shows promise as a predictor of chemotherapy response and survival benefit in women with invasive breast cancer, according to research led by The University of Texas MD Anderson Cancer Center.

11 May 2011

UCLA researchers amp up power of killer CD8 T-cells to fight melanoma

Researchers with UCLA's Jonsson Comprehensive Cancer Center have discovered a way to amp up the power of killer T-cells, called CD8 cells, making them more functional for longer periods of time and boosting their ability to multiply and expand within the body to fight melanoma, a new study has found.

11 May 2011

Coffee consumption can reduce risk of ER-negative breast cancer in women

Recently published research shows that coffee drinkers enjoy not only the taste of their coffee but also a reduced risk of cancer with their cuppa. More detailed research published today in BioMed Central's open access journal Breast Cancer Research shows that drinking coffee specifically reduces the risk of antiestrogen-resistant estrogen-receptor-negative breast cancer.

11 May 2011

Simcere first quarter total revenue increases 5.1% to RMB482.2 million

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today reported unaudited financial results for the first quarter ended March 31, 2011.

10 May 2011

IUPUI psychology professor to receive 2011 Young Scientist award for alcoholism research

Stephen L. Boehm II, Ph.D., associate professor of psychology in the School of Science at Indiana University-Purdue University Indianapolis, has been named the 2011 Young Scientist of the Year by the International Behavioural and Neural Genetics Society. The award will be presented May 13 at the society's annual meeting in Rome, Italy.

10 May 2011

biocrea and Pfizer jointly presented details on novel PDE10 inhibitors

biocrea, a biopharmaceutical company focusing on novel treatments for disorders of the central nervous system (CNS), today reported details on the design and synthesis of novel, brain-penetrating phosphodiesterase-10 (PDE10) inhibitors developed in collaboration with Pfizer Inc. (NYSE: PFE). The data were featured in joint presentations1 with Pfizer at the recent 241st ACS National Meeting & Exposition, an event organized by the American Chemical Society (ACS).

10 May 2011

Treatment with estrogen-lowering drugs shrinks tumors and reduces mastectomy rates in breast cancer patients

In the first large trial of its kind in the United States, researchers have shown that estrogen-lowering drugs can shrink tumors and reduce mastectomy rates for patients with stage 2 or 3 breast cancer.

10 May 2011

Acceleron presents RAP-661 preclinical data in osteopenic mice at international meeting

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, presented preclinical data highlighting the significant anabolic bone effects in normal and osteopenic mice of RAP-661.

10 May 2011

Scientists reveal nerve cells' navigation system

Johns Hopkins scientists have discovered how two closely related proteins guide projections from nerve cells with exquisite accuracy, alternately attracting and repelling these axons as they navigate the most miniscule and frenetic niches of the nervous system to make remarkably precise connections.

9 May 2011

GTx reports net loss of $2.6 million for first quarter 2011

GTx, Inc. today provided a company update and reported financial results for the first quarter of 2011.

9 May 2011

Heptares, Shire sign deal to develop novel A2A antagonist for CNS disease treatment

Heptares Therapeutics today announced it has signed an exclusive option agreement with Shire Pharmaceuticals for a novel adenosine A2A antagonist discovered by Heptares and currently in preclinical development.

9 May 2011

NYU Langone researchers present recent findings at The Heart Rhythm Society 32nd annual sessions

Cardiologists from the Cardiac & Vascular Institute at NYU Langone Medical Center presented new research at The Heart Rhythm Society's 32nd Annual Scientific Sessions, May 4 -7 in San Francisco, California.

9 May 2011

Breast cancer linked to lifestyle & three new genes

According to the latest research as many as 20,000 British women could avoid developing breast cancer if they took more exercise, drank less and ate better. The World Cancer Research Fund recommends taking half an hour of physical exercise a day, limiting alcohol consumption to just one drink daily and losing weight.

8 May 2011

Receptor News and Research

UCSD scientists discover steroid hormone that inhibits brain inflammation

Coffee provides protections from a type of breast cancer: Study

Researchers help explain why smart drugs are not effective in some cancer patients

Losartan therapy improves muscle injury regeneration and prevents disuse atrophy

Amira to present AM152 preclinical data in fibrotic disease at ATS Annual Meeting

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Naurex announces completion of $18 million Series A financing

Women with invasive breast cancer can benefit from new genomic test

UCLA researchers amp up power of killer CD8 T-cells to fight melanoma

Coffee consumption can reduce risk of ER-negative breast cancer in women

Simcere first quarter total revenue increases 5.1% to RMB482.2 million

IUPUI psychology professor to receive 2011 Young Scientist award for alcoholism research

biocrea and Pfizer jointly presented details on novel PDE10 inhibitors

Treatment with estrogen-lowering drugs shrinks tumors and reduces mastectomy rates in breast cancer patients

Acceleron presents RAP-661 preclinical data in osteopenic mice at international meeting

Scientists reveal nerve cells' navigation system

GTx reports net loss of $2.6 million for first quarter 2011

Heptares, Shire sign deal to develop novel A2A antagonist for CNS disease treatment

NYU Langone researchers present recent findings at The Heart Rhythm Society 32nd annual sessions

Breast cancer linked to lifestyle & three new genes

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News